This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignees: F. Hoffmann-La Roche Ag, Health Research, Inc.. Active years: 2017.
Company Filing History:
1 out of 180 
1 out of 313 Years Active: 2017
Title: Innovations of Eugene Kandel in Hypoxia Research
Introduction
Eugene Kandel is a notable inventor based in Williamsville, NY (US). He has made significant contributions to the field of medical research, particularly in the area of hypoxia-induced damage. His innovative work has led to the development of methods and compositions aimed at inhibiting the detrimental effects of hypoxia.
Latest Patents
Eugene Kandel holds a patent for "Compositions and methods for inhibiting hypoxia-induced damage." This patent involves the use of various agents that can inhibit specific genes associated with hypoxia, including BCL2L14, BLOC1S2, C20RF42, CPT1A, FBP1, GCNT3, RHOB, SCIN, TACR1, and TNFAIP6. The methods described in the patent include introducing gene-inhibiting agents to cells, tissues, organs, or individuals to prevent hypoxia-related damage. Additionally, the patent encompasses kits containing these agents along with instructions for their use.
Career Highlights
Throughout his career, Eugene Kandel has worked with reputable organizations such as Health Research, Inc. and F. Hoffmann-La Roche AG. His experience in these companies has allowed him to collaborate with other professionals in the field and contribute to groundbreaking research.
Collaborations
Eugene has collaborated with notable coworkers, including Evan Zynda and Brigitte Schott. These partnerships have further enhanced his research and innovation in the medical field.
Conclusion
Eugene Kandel's work in developing methods to inhibit hypoxia-induced damage showcases his dedication to advancing medical research. His contributions have the potential to significantly impact the treatment of conditions related to hypoxia.